Literature DB >> 22581531

Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.

Luciano Merlini1, Monia Gennari, Elisabetta Malaspina, Ilaria Cecconi, Annarita Armaroli, Saverio Gnudi, Beril Talim, Alessandra Ferlini, Alessandro Cicognani, Emilio Franzoni.   

Abstract

INTRODUCTION: Corticosteroid treatment is the standard of care in Duchenne muscular dystrophy (DMD), but the optimal age to initiate treatment and dosage pattern remain a matter of discussion.
METHODS: We performed a long-term study of alternate-day corticosteroids in five 2- to 4-year-old DMD patients. The primary outcome measure was prolongation of the ability to walk.
RESULTS: One patient lost ambulation at age 10. Four patients, aged 16 to 18 were fully ambulant, and 3 of them could still climb stairs. Respiratory function was moderately reduced in 2. Left ventricular ejection fraction was > 45%. Short stature and delayed puberty were the most relevant side effects. Although the negative impact of corticosteroid treatment on growth rate remained their major concern, parents and patients stated that they preferred corticosteroid therapy.
CONCLUSIONS: Long-term corticosteroid treatment is effective in prolonging function but not in recovering lost function, and its early use seems appropriate.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22581531     DOI: 10.1002/mus.23272

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  37 in total

Review 1.  What can Duchenne Connect teach us about treating Duchenne muscular dystrophy?

Authors:  Richard T Wang; Stanley F Nelson
Journal:  Curr Opin Neurol       Date:  2015-10       Impact factor: 5.710

Review 2.  Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; David R Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-02       Impact factor: 3.243

3.  Leg muscle MRI in identical twin boys with duchenne muscular dystrophy.

Authors:  Rebecca J Willcocks; William T Triplett; Donovan J Lott; Sean C Forbes; Abhinandan Batra; H Lee Sweeney; Jerry R Mendell; Krista Vandenborne; Glenn A Walter
Journal:  Muscle Nerve       Date:  2018-01-24       Impact factor: 3.217

Review 4.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; David Brumbaugh; Laura E Case; Paula R Clemens; Stasia Hadjiyannakis; Shree Pandya; Natalie Street; Jean Tomezsko; Kathryn R Wagner; Leanne M Ward; David R Weber
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

5.  Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.

Authors:  Kenji Rowel Q Lim; Yusuke Echigoya; Tetsuya Nagata; Mutsuki Kuraoka; Masanori Kobayashi; Yoshitsugu Aoki; Terence Partridge; Rika Maruyama; Shin'ichi Takeda; Toshifumi Yokota
Journal:  Mol Ther       Date:  2018-10-19       Impact factor: 11.454

6.  Clinical Follow-Up for Duchenne Muscular Dystrophy Newborn Screening: A Proposal.

Authors:  Jennifer M Kwon; Hoda Z Abdel-Hamid; Samiah A Al-Zaidy; Jerry R Mendell; Annie Kennedy; Kathi Kinnett; Valerie A Cwik; Natalie Street; Julie Bolen; John W Day; Anne M Connolly
Journal:  Muscle Nerve       Date:  2016-06-13       Impact factor: 3.217

Review 7.  Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment.

Authors:  Qing Ke; Zheng-Yan Zhao; Robert Griggs; Veronica Wiley; Anne Connolly; Jennifer Kwon; Ming Qi; Daniel Sheehan; Emma Ciafaloni; R Rodney Howell; Petra Furu; Peter Sazani; Arvind Narayana; Michele Gatheridge
Journal:  World J Pediatr       Date:  2017-05-17       Impact factor: 2.764

8.  Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy.

Authors:  David R Weber; Stasia Hadjiyannakis; Hugh J McMillan; Garey Noritz; Leanne M Ward
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

9.  Nanotopography-responsive myotube alignment and orientation as a sensitive phenotypic biomarker for Duchenne Muscular Dystrophy.

Authors:  Bin Xu; Alessandro Magli; Yoska Anugrah; Steven J Koester; Rita C R Perlingeiro; Wei Shen
Journal:  Biomaterials       Date:  2018-08-21       Impact factor: 12.479

10.  A membrane glucocorticoid receptor mediates the rapid/non-genomic actions of glucocorticoids in mammalian skeletal muscle fibres.

Authors:  María Hernández-Alcalá Pérez; Jonathan Cormack; David Mallinson; Gabriel Mutungi
Journal:  J Physiol       Date:  2013-07-22       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.